Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of BGJ398 in Combination Modified FOLFIRINOX in Treatment-Naïve Metastatic Pancreatic Cancer Patients

NCT02575508 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02575508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02575508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of BGJ398 in Combination Modified FOLFIRINOX in Treatment-Naïve Metastatic Pancreatic Cancer Patients
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1/2
Overall status
Withdrawn
Start date
Not reported
Completion date
Not reported
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon adenocarcinoma, metastatic pancreatic adenocarcinoma, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, rectal adenocarcinoma, stage iii pancreatic cancer, stage iiia colon cancer, stage iiia rectal cancer, stage iiib colon cancer, stage iiib rectal cancer, stage iiic colon cancer, stage iiic rectal cancer, stage iv pancreatic cancer, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer